This has been demonstrated to reduce the efficacy of T-cell-mediated immunotherapies.8 Similarly, the loss of a tumor suppressor gene PTEN, which enhances PI3K signaling to promote malignant cell proliferation, is common in many cancers and effectively contributes to resistance against checkpoint inhibitors. This evidence concerns the gene PTEN and cancer.